NASDAQ$SAGE
Sage Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Sage reported a decrease in net loss and an increase in collaboration revenue for the fourth quarter and full year 2024.
Sage Therapeutics reported a net loss of $95.8 million for the fourth quarter of 2024, an improvement from $32.7 million in the same period of 2023. Collaboration revenue from ZURZUVAE significantly increased to $11.4 million in Q4 2024, up from $0.8 million in Q4 2023, indicating strong initial growth for the new treatment. The company also saw a substantial increase in ZURZUVAE shipments, with nearly 2,500 prescriptions delivered in Q4 2024.
- ZURZUVAE collaboration revenue reached $11.4 million in Q4 2024, a significant increase from $0.8 million in Q4 2023.
- Net loss for Q4 2024 was $95.8 million, compared to $32.7 million in Q4 2023.
- Nearly 2,500 ZURZUVAE prescriptions were shipped in Q4 2024, representing a 21% increase from Q3 2024.
- Cash, cash equivalents, and marketable securities stood at $504 million as of December 31, 2024, with a cash runway expected to support operations to mid-2027.
Headline financials
Revenue & EPS history
Sage · Revenue · Quarterly
$12.8M
Revenue by segment
Sage · $1.64M total across 1 segment · Q4 2021
- ZULRESSO Net Revenue$1.64M—100.0%
Forward guidance
Sage Therapeutics anticipates its existing cash, cash equivalents, and marketable securities, along with anticipated funding from collaborations and estimated revenues, will support operations until mid-2027. The company expects overall operating expenses to decrease in 2025 due to reductions in R&D and G&A, pipeline prioritization, and cost savings from the October 2024 reorganization.
Tailwinds
- Existing cash, cash equivalents, and marketable securities, combined with anticipated funding and estimated revenues, are expected to support operations to mid-2027.
- Overall operating expenses are anticipated to substantially decrease in 2025 compared to 2024.
- Reductions in R&D and G&A expenses are expected in 2025.
- Cost savings from the October 2024 reorganization are expected to be realized, with the first full quarter of savings in Q1 2025.
- ZURZUVAE joint commercialization investment will increase in 2025, indicating continued focus on market expansion.
Headwinds
- Commercialization efforts for ZURZUVAE may not be successful, potentially failing to generate expected revenues or achieve goals.
- The number of women with PPD, unmet need, and market potential for ZURZUVAE may be smaller than anticipated.
- ZURZUVAE may not achieve or maintain expected clinical benefit, clinical use, or market acceptance, or may face reimbursement, market access, or distribution issues.
- Delays in clinical trials, unexpected data, or regulatory actions could impact timelines, costs, and development success.
- Adverse events, collaboration issues, or higher-than-expected costs could negatively affect business and cash usage.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2024
-2.8%
Avg return
Earnings day
-5.3%
Avg return
5 days after
-6.4%
Avg return
30 days after
43%
19 / 44 earnings
Positive
+12.4%
Q4 2021
Best reaction
-47.6%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | — | — | — | |
| Q1 2025 | -4.1% | -5.7% | -15.0% | |
| Q4 2024 | -0.4% | -0.8% | +7.2% | |
| Q3 2024 | -24.6% | -29.1% | -35.2% | |
| Q2 2024 | -9.6% | -17.2% | -22.1% | |
| Q1 2024 | -2.2% | -0.6% | -19.4% | |
| Q4 2023 | +10.4% | +1.3% | -13.2% | |
| Q3 2023 | -10.2% | -17.1% | +1.3% | |
| Q2 2023 | -47.6% | -39.7% | -42.8% | |
| Q1 2023 | -2.4% | +0.9% | +1.9% | |
| Q4 2022 | +0.9% | -5.2% | -5.2% | |
| Q3 2022 | -5.0% | +5.0% | +16.5% | |
| Q2 2022 | +4.6% | +21.6% | +12.8% | |
| Q1 2022 | +4.9% | -12.2% | +12.6% | |
| Q4 2021 | +12.4% | +12.3% | -1.0% | |
| Q3 2021 | +11.2% | +6.4% | -9.7% | |
| Q2 2021 | -4.0% | -5.1% | +9.0% | |
| Q1 2021 | -10.3% | — | — | |
| Q4 2020 | +4.0% | — | — | |
| Q3 2020 | -0.6% | — | — | |
| Q2 2020 | +1.3% | — | — | |
| Q1 2020 | -4.1% | — | — | |
| Q4 2019 | -26.2% | — | — | |
| Q3 2019 | -0.2% | — | — | |
| Q2 2019 | +7.4% | — | — | |
| Q1 2019 | +0.3% | — | — | |
| Q4 2018 | -8.2% | — | — | |
| Q3 2018 | +3.0% | — | — | |
| Q2 2018 | -0.7% | — | — | |
| Q1 2018 | +1.2% | — | — | |
| Q4 2017 | +0.2% | — | — | |
| Q3 2017 | +11.7% | — | — | |
| Q2 2017 | +7.7% | — | — | |
| Q1 2017 | -2.7% | — | — | |
| Q4 2016 | +0.6% | — | — | |
| Q3 2016 | +0.5% | — | — | |
| Q2 2016 | -13.3% | — | — | |
| Q1 2016 | -3.8% | — | — | |
| Q4 2015 | -4.8% | — | — | |
| Q3 2015 | -4.6% | — | — | |
| Q2 2015 | -6.5% | — | — | |
| Q1 2015 | +2.0% | — | — | |
| Q4 2014 | +2.1% | — | — | |
| Q3 2014 | -5.2% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro